Alpha Cubed Investments LLC Sells 1,187 Shares of Eli Lilly and Company (NYSE:LLY)

Alpha Cubed Investments LLC trimmed its stake in Eli Lilly and Company (NYSE:LLY) by 7.1% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,511 shares of the company’s stock after selling 1,187 shares during the period. Alpha Cubed Investments LLC’s holdings in Eli Lilly and Company were worth $9,042,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of LLY. Lipe & Dalton bought a new position in shares of Eli Lilly and Company in the fourth quarter worth about $26,000. Thompson Investment Management Inc. purchased a new stake in Eli Lilly and Company in the 3rd quarter worth approximately $27,000. Legacy Financial Group LLC bought a new stake in Eli Lilly and Company during the 3rd quarter worth approximately $35,000. Optiver Holding B.V. bought a new stake in Eli Lilly and Company during the 3rd quarter worth approximately $36,000. Finally, Family CFO Inc bought a new stake in Eli Lilly and Company during the 3rd quarter worth approximately $40,000. 82.53% of the stock is owned by institutional investors.

Analysts Set New Price Targets

LLY has been the topic of a number of recent analyst reports. Cantor Fitzgerald restated an “overweight” rating and set a $885.00 target price (up previously from $815.00) on shares of Eli Lilly and Company in a research note on Tuesday. BMO Capital Markets raised their target price on shares of Eli Lilly and Company from $710.00 to $865.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 7th. Citigroup raised their target price on shares of Eli Lilly and Company from $675.00 to $895.00 and gave the stock a “buy” rating in a research note on Tuesday, April 2nd. Erste Group Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Wednesday, April 3rd. Finally, TheStreet upgraded shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a research report on Friday, March 8th. Three equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $731.55.

Insiders Place Their Bets

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 78,573 shares of Eli Lilly and Company stock in a transaction on Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total transaction of $50,920,804.11. Following the completion of the transaction, the insider now directly owns 99,333,810 shares of the company’s stock, valued at $64,375,262,246.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 0.13% of the stock is owned by insiders.

Eli Lilly and Company Price Performance

LLY traded up $44.36 during trading hours on Tuesday, hitting $781.56. The company’s stock had a trading volume of 7,432,651 shares, compared to its average volume of 3,071,009. The business’s 50-day moving average price is $760.89 and its 200-day moving average price is $668.00. Eli Lilly and Company has a 12 month low of $392.26 and a 12 month high of $800.78. The stock has a market cap of $742.61 billion, a price-to-earnings ratio of 134.43, a P/E/G ratio of 1.60 and a beta of 0.34. The company has a current ratio of 0.94, a quick ratio of 0.73 and a debt-to-equity ratio of 1.69.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, topping the consensus estimate of $2.30 by $0.19. The company had revenue of $9.35 billion during the quarter, compared to analyst estimates of $8.95 billion. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. Eli Lilly and Company’s quarterly revenue was up 28.1% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.09 earnings per share. Sell-side analysts expect that Eli Lilly and Company will post 12.51 earnings per share for the current fiscal year.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.